Revefenacin (trade name Yupelri) is a pharmaceutical drug for the treatment of COPD.
Posted at2023-11-30
Currently, chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide and is common in resource-poor countries.
Revefenacin (trade name Yupelri) is a pharmaceutical drug for the treatment of COPD. It was approved for use in the United States in 2018.

Inhaled revefenacin is a long-acting bronchodilator. This medicine is breathed in through the mouth to open up the bronchial tubes (air passages) in the lungs. 

It relieves cough, wheezing, and troubled breathing by increasing the flow of air through the bronchial tubes.

We have achieved the research on the intermediate of Revefenacin:

Revefenacin API 864750-70-9
Revefenacin intermediate 107201-33-2

If any demand,welcome to contact for more information!

What is COPD (chronic obstructive pulmonary disease)?

COPD is an umbrella term for a range of progressive lung diseases. Chronic bronchitis and emphysema can both result in COPD. A COPD diagnosis means you may have one of these lung-damaging diseases or symptoms of both. COPD can progress gradually, making it harder to breathe over time.

Who gets COPD?

The primary, or main, cause of COPD is smoking. But not all smokers develop the disease. You may be at higher risk if you:

  • Are someone who was assigned female at birth.
  • Are over the age of 65.
  • Have been exposed to air pollution.
  • Have worked with chemicals, dust or fumes.
  • Have alpha-1 antitrypsin deficiency (AAT), a genetic risk factor for COPD.
  • Had many respiratory infections during childhood.

Symptoms and Causes

COPD Overview

What causes COPD?

Smoking tobacco causes up to 90% of COPD cases. Other causes include:

  • Alpha-1 antitrypsin (AAT) deficiency, a genetic disorder.
  • Secondhand smoke.
  • Air pollution.
  • Workplace dust and fumes.


Tobacco smoke irritates airways, triggering inflammation (irritation and swelling) that narrows the airways. Smoke also damages cilia so they can’t do their job of removing mucus and trapped particles from the airways.

AAT deficiency

AAT (alpha-1 antitrypsin deficiency) is an uncommon, inherited disorder that can lead to emphysema. Alpha-1 antitrypsin is an enzyme that helps protect your lungs from the damaging effects of inflammation. When you have AAT deficiency, you don’t produce enough of alpha-1 antitrypsin. Your lungs are more likely to become damaged from exposure to irritating substances like smoke and dust. It’s not possible to distinguish COPD related to alpha-1 antitrypsin deficiency from common COPD. Therefore, all people with COPD should get screened for AAT deficiency with a blood test.

What are the signs and symptoms of chronic obstructive pulmonary disease?

  • Cough with mucus that persists for long periods of time.
  • Difficulty taking a deep breath.
  • Shortness of breath with mild exercise (like walking or using the stairs).
  • Shortness of breath performing regular daily activities.
  • Wheezing.

Copyright 2016 Speranza Chemical Co., Ltd. All rights reserved.